Welcome to our dedicated page for Celcuity SEC filings (Ticker: CELC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Celcuity Inc. (NASDAQ: CELC) SEC filings page provides access to the company’s official regulatory disclosures as a clinical-stage biotechnology company developing targeted therapies for oncology. Through these documents, investors can review how Celcuity reports its progress with gedatolisib, a multi-target PI3K/AKT/mTOR (PAM) inhibitor being evaluated in multiple solid tumor indications, including HR+/HER2- advanced breast cancer and metastatic castration resistant prostate cancer.
Celcuity’s recent Form 8-K filings highlight material clinical and regulatory events, such as detailed results from the Phase 3 VIKTORIA-1 trial in HR+/HER2-/PIK3CA wild-type advanced breast cancer, updates on the fully enrolled PIK3CA mutant cohort, and clinical data from early phase studies of gedatolisib in combination with darolutamide. Other 8-Ks describe the submission of a New Drug Application (NDA) to the U.S. FDA for gedatolisib in HR+/HER2-/PIK3CA wild-type advanced breast cancer under the Real-Time Oncology Review program, as well as quarterly financial results and corporate updates.
Filings also detail financing and capital structure transactions, including public offerings of common stock and pre-funded warrants, issuance of 2.750% Convertible Senior Notes due 2031, and amendments to Celcuity’s senior secured term loan facility with lenders such as Oxford Finance LLC and Innovatus Life Sciences Lending Fund I, LP. These documents describe new term loan tranches, warrant issuances, and conditions tied to regulatory milestones and product revenue thresholds.
On Stock Titan, users can track Celcuity’s SEC filings as they are posted to EDGAR and use AI-powered summaries to quickly interpret key points from lengthy reports. This includes understanding the implications of 8-K event disclosures, financial condition updates, loan agreement amendments, and equity or debt offerings related to the company’s efforts to advance and potentially commercialize gedatolisib.
Celcuity Inc. (CELC) filed an 8-K detailing several capital-raising and financing actions dated 28 Jul 2025.
Loan amendment: The company executed a Second Amendment to its Amended & Restated Loan and Security Agreement with Innovatus and Oxford Finance. Key changes: (i) allows issuance of $150 m aggregate principal Convertible Senior Notes due 2031 and related capped-call transactions; (ii) permits equity conversion of the notes solely into common shares (cash only for fractional shares); (iii) requires a one-time $25 k amendment fee paid to Oxford; and (iv) extends to 9 May 2026 Innovatus’ option to convert up to 20 % of Term A principal into CELC stock at $10.00 per share.
Capital markets activity: Celcuity launched a concurrent offering for $150 m of the Notes plus $75 m of common stock. Proceeds would strengthen liquidity and fund operations.
Additional debt capacity: Management believes the Phase 3 VIKTORIA-1 data achieve the “Term D Milestone,” enabling a $30 m Term D Loan draw by 31 Aug 2025.
Preliminary cash position: Cash, equivalents and short-term investments are expected at ~<$168.4 m> on 30 Jun 2025 versus $283.1 m a year earlier (-41 %). Figures are unaudited and subject to change.
Forward-looking statements caution that the offerings may not close, the Term D draw might not occur, and final June-quarter financials could differ.
Celcuity Inc. (CELC) filed a Form 144 indicating an intention to sell up to 100,000 common shares through RBC Capital Markets on or about 28 Jul 2025. At the filing’s reference price, the shares have an aggregate market value of $4.398 million and represent roughly 0.3 % of the 37.87 million shares outstanding.
The shares were originally acquired on 28 Feb 2014 via an investment transaction paid by check. The filer reports no sales of Celcuity securities in the past three months. The notice states that the seller is unaware of any undisclosed material adverse information and affirms compliance with Rule 10b5-1 if applicable. The planned sale will take place on the NASDAQ exchange. No additional financial data, earnings information, or prior insider transactions are disclosed in this filing.
FAQ
What is the current stock price of Celcuity (CELC)?
What is the market cap of Celcuity (CELC)?
